Top Marijuana Stocks Under $10: Which Performers Deserve Your Attention

The cannabis industry continues to present compelling investment opportunities, particularly in the sub-$10 price range where you can build meaningful positions with modest capital. A $100 investment could yield 10+ shares, while $1,000 could secure 100 or more shares of established operators. This accessibility combined with the industry’s expansion potential makes affordable marijuana stocks attractive to growth-focused investors. Based on recent market data and industry performance, four standout companies merit attention: Cresco Labs (OTC: CRLBF), Village Farms (NASDAQ: VFF), Tilray (NASDAQ: TLRY), and Curaleaf (OTC: CURLF).

As cannabis legalization continues to sweep North America, these operators are positioned at different stages of their growth trajectories. Each brings distinct advantages—from regional market dominance to multi-state scale to diversified revenue streams. Here’s what makes each relevant for those considering exposure to marijuana stocks under $10.

Cresco Labs: Illinois Market Momentum

Chicago-based Cresco Labs exemplifies how regional legalization can drive explosive growth. Since Illinois legalized adult-use cannabis in 2019, the market has demonstrated remarkable expansion. Tax revenue collection surpassed $100 million, with recreational sales climbing from $39.2 million in early periods to $67.6 million monthly during peak seasons.

Cresco captured significant upside from this boom, with nine established dispensaries across Illinois plus additional expansion underway. The company’s strategic positioning—including a location near iconic Wrigley Field—demonstrates its focus on high-traffic areas. During the first half of 2020, Cresco reported sales of $160.6 million, representing a tripling of the $50.9 million generated in the comparable prior-year period.

Growth has come through both organic expansion and strategic acquisitions, including the Origin House deal. Cresco’s brand portfolio spans premium products, edibles, and medical-focused offerings, enabling the company to capture demand across consumer segments. At that time, the stock traded near $7.50 and showed momentum, highlighting the company’s ability to translate market opportunity into revenue growth.

Village Farms: Pure Sunfarms Acquisition Transforms the Platform

Village Farms took a transformational step when it acquired complete control of Pure Sunfarms, a low-cost cannabis producer based in British Columbia. Previously operating as a joint venture with Emerald Therapeutics, the company completed its full buyout in September for 79.9 million Canadian dollars, gaining 100% ownership of the greenhouse operation.

This acquisition fundamentally changed Village Farms’ financial profile. Pure Sunfarms generated $7 million in net income on net sales of approximately $22 million during the first half of 2020—a 31% profit margin that far exceeds typical industry levels. Previously, when Village Farms held only partial ownership, the operation contributed just under $4 million to its bottom line.

With full control of Pure Sunfarms’ efficient operations, Village Farms shifted from a chronically unprofitable company to a near-breakeven position by mid-year. The company reported $4.1 million in profit during the first half of 2020, with Pure Sunfarms accounting for the bulk of earnings. This acquisition made Village Farms a compelling turnaround candidate, trading around $5 at the time despite showing decline year-to-date. Standalone operations contributed $79.7 million in sales, growing 9% annually, but the Pure Sunfarms contribution positioned the company toward sustainable profitability.

Tilray: Diversified Revenue Model Reduces Concentration Risk

Tilray stands apart among marijuana stocks under $10 due to its unusually diversified business model. Rather than relying solely on one revenue stream, the company operates across multiple segments: adult-use cannabis, medical marijuana, international markets, and hemp-derived products.

During the first half of 2020, Tilray generated $102.5 million in year-to-date sales, reflecting 49% year-over-year growth. Cannabis sales reached $60.9 million (up 40%), while hemp revenue climbed to $41.6 million (up 63%). Notably, hemp revenues of $20.2 million in Q2 2020 actually exceeded adult-use cannabis revenue of $17.6 million, demonstrating the company’s meaningful business diversification.

This multi-segment approach provides both opportunity and complexity. Investors gain exposure to various cannabis market segments simultaneously, reducing dependence on any single category. However, the mixed performance across segments can make forecasting difficult. Tilray’s losses totaled $265.8 million in the first two quarters of 2020, though impairment charges and fair value adjustments significantly impacted reported results. At approximately $6 per share, Tilray represented a higher-risk opportunity with contrarian appeal if the company could demonstrate improving profitability.

Curaleaf: Multi-State Scale and National Footprint

Curaleaf operates on a fundamentally different scale than its peers, functioning as a true multi-state operator spanning 23 states with 95 dispensaries. This national footprint positions the company to benefit from expanding legalization across the country. Additional growth catalysts emerged as voters in Arizona, Montana, New Jersey, and South Dakota considered recreational legalization measures, while other states evaluated medical marijuana approval.

The company’s growth trajectory has been remarkable. During the first half of 2020, Curaleaf reported total revenue of $214 million—a 156% increase from $83.7 million in the same 2019 period. Despite this aggressive expansion, the company moved toward profitability: its year-to-date loss of $17.1 million represented substantial improvement from the $34.8 million loss posted in 2019.

Curaleaf has accelerated growth through strategic acquisitions, closing on Cura Partners (owner of the Select brand) and Grassroots during 2020. The company expanded the Select brand nationally, launching in Ohio as the 14th state where the brand operates. At approximately $9 per share, Curaleaf appeared poised to move above the $10 threshold given its growth momentum, making it potentially the shortest-lived candidate among affordable marijuana stocks under $10.

Building Your Cannabis Portfolio Strategy

These four companies each offer distinct characteristics for investors considering exposure to the cannabis opportunity. Cresco Labs appeals to those seeking regional growth leverage. Village Farms attracts those focused on operational leverage and acquisition-driven transformation. Tilray suits investors desiring business model diversification. Curaleaf serves those seeking scale and national exposure.

The broader cannabis legalization trend continues reshaping North American markets, creating recurring investment cycles. The marijuana stocks under $10 category will likely feature fresh opportunities as new states advance legalization and established operators expand into emerging markets. These four examples demonstrate how different approaches to market opportunity have historically produced compelling returns for patient investors in the cannabis sector.